Applied Materials Target REDUCED and 4 Must-See New Analysis Ratings

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Applied Materials Inc. (NASDAQ:AMAT) saw its price target lowered by Argus, following the firm’s reduction of its guidance, a move to which it attributes industry-wide negative factors. Further, AMAT predicts that any lessening in semiconductor demand should last for only a short term . Argus keeps its Buy rating on Applied Materials.

Don’t Miss: Did Apple STEAL From This Company?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is expected by Rodman & Renshaw to disclose data from a Phase I trial of its investigational treatment for familial amyloidotic polyneuropathy prior to August. The analysts believe that the data release will be a shot in the arm for shares, and restates its Outperform and $19 price target on Alnylam.

MBIA Inc. (NYSE:MBI) reported that New York had not yet okayed a scheduled interest payment on the firm’s surplus notes, but subsequently MKM Partners commented that the company will neither go bankrupt nor become insolvent if it’s unable to make the payment. In actuality missing the payment would only strengthen the position of policy holders at the expense of surplus note holders. MKM keeps an $18 target and Buy on MBIA.

SanDisk Corp. (NASDAQ:SNDK) and Micron (NASDAQ:MU) conjure up visions of risk to JPMorgan, which now believes that NAND revenue will shrink by 4 percent in 2012 and by 12 percent in 2013, which are well under its previous estimates. The firm remains cautious on the two, however.

Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) was mentioned positively by Piper Jaffray.

Don’t Miss: BRACE YOURSELF: The Mini-Tablet WAR is Heating Up.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business